AMENDMENTS TO THE CLAIMS

Please amend claims 1-15, 20-22, 24, and 25 as indicated below. Please also cancel claims 16-19 without prejudice or disclaimer. Deletions appear in ~~strikethrough font~~, and additions are underlined. The listing of claims below will replace all prior versions and listings of claims in the application.

Complete listing of claims

1. (Currently Amended) A compound of formula (I):



(I)

wherein:

- G is a COOH group or a tetrazolyl group;
- R1 and R2 are each independently ~~selected~~ chosen from hydrogen atoms, and alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, cycloalkenyl, cycloalkenylalkyl, cycloalkenylalkenyl, cycloalkenylalkynyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, ~~or~~ and heteroarylalkynyl groups;

- or R1 and R2 form, together with the nitrogen atom to which they are attached, either a 3- to 14- membered monocyclic or polycyclic heterocyclic ring system or a 5- to 14- membered heteroaryl group;

  wherein each of said ~~groups~~ 3- to 14- membered monocyclic or polycyclic heterocyclic ring system, or 5- to 14- membered heteroaryl group comprises from 1 to 5 heteroatoms ~~selected~~chosen from nitrogen, oxygen and sulphur;

wherein each of said alkyl, alkenyl, and alkynyl groups ~~or moieties are~~ is independently unsubstituted or substituted with one to four substituents, ~~which~~ wherein said one to four substituents may be the same or different and each is ~~are~~ independently ~~selected~~chosen from Ra;

and wherein each of said cycloalkyl, heterocyclyl, aryl and heteroaryl groups ~~or moieties are~~ is independently unsubstituted or substituted with one to four substituents, ~~which~~ wherein said one to four substituents may be the same or different and each is ~~are~~ independently ~~selected~~chosen from Rb;

- R3 and R4 are each independently ~~selected~~chosen from hydrogen atoms and alkyl groups having from 1 to 6 carbon atoms;
- R5 is ~~selected~~chosen from ~~the group consisting of~~ 6- to 14- membered monocyclic or polycyclic aryl groups and 5- to 14- membered monocyclic or polycyclic heteroaryl groups comprising from 1 to 5 heteroatoms ~~selected~~chosen from nitrogen, oxygen and sulphur;

wherein each of said aryl and heteroaryl groups or moieties ~~are~~ is independently unsubstituted or substituted with one to four substituents, ~~which~~wherein said one to four substituents may be the same or different and ~~are~~ each is independently ~~selected~~chosen from Rb;

- R6 is a group ~~selected~~chosen from -OH, -ORc, -NO_2, halogen, -S(O)Rc, -$S(O)_2$Rc, -SRc, -$S(O)_2$ORc, -S(O)NRcRc -$S(O)_2$NRcRc, -NRcRc, -O(CRcRc)mNRcRc, -C(O)Rc, –CO_2Rc, -CO_2(CRcRc)mCONRcRc, -OC(O)Rc, -CN, -C(O)NRcRc, -NRcC(O)Rc, -OC(O)NRcRc, -NRcC(O)ORc, -NRcC(O)NRcRc, -CRc(N-ORc), -CFH_2, -CF_2H, -Ra, -CF_3, alkyl, alkenyl and alkynyl;
- n is an integer from 0 to 3
- Ra is a group ~~selected~~chosen from alkyl, -OH, -ORc, -NO_2, halogen, -S(O)Rc, -$S(O)_2$Rc, -SRc, -$S(O)_2$ORc, S(O)NRcRc, -$S(O)_2$NRcRc, -NRcRc, -O(CRcRc)mNRcRc, -C(O)Rc, -CO_2Rc, -CO_2(CRcRc)mCONRcRc, -OC(O)Rc, -CN, -C(O)NRcRc, -NRcC(O)Rc, -OC(O)NRcRc, -NRcC(O)ORc, -NRcC(O)NRcRc, -CRc(N-ORc), -CFH_2, - CF_2H, -Ra, ~~or~~ and -CF_3 ; wherein if two or more Rc groups are present these Rc groups may be the same or different;
- Rb is a group ~~selected~~chosen from -OH, -ORd, -NO_2, halogen, -S(O)Rd, -$S(O)_2$Rd ,- SRd, -$S(O)_2$ORd,- S(O)NRdRd, -$S(O)_2$NRdRd, -NRdRd,-O(CRdRd)mNRdRd, -C(O)Rd, -CO_2Rd, -CO_2(CRdRd)mCONRdRd, -OC(O)Rd, -CN, -C(O)NRdRd, -NRdC(O)Rd, -OC(O)NRdRd, -NRdC(O)ORd, -

NRdC(O)NRdRd, -CRd(N-ORd), $-CFH_2$, $-CF_2H$, -Ra, $-CF_3$, alkyl, alkenyl, C_{2-4}alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl ~~or~~ and heteroarylalkyl; wherein each of said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups ~~or moieties are~~ is independently unsubstituted or substituted with one to four substituents; ~~which~~ wherein said one to four substituents may be the same or different and ~~are~~ each is independently ~~selected~~chosen from Ra;

- L1 is either a direct bond or a group ~~selected~~chosen from ~~the group consisting of~~ N(Rc)-, -O-, -N(Rc)CO-, -CON(Rc)-, -O(CO)N(Rc)- and -N(Rc)(CO)O-;
- Rc is a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms;
- Rd is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, cycloalkenyl, cycloalkenylalkyl, cycloalkenylalkenyl, cycloalkenylalkynyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, or heteroarylalkynyl;

wherein each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl and heteroaryl groups ~~are~~ is independently unsubstituted or substituted with one to four substituents; ~~which~~ wherein said one to four substituents may be the same or different and ~~are~~ each is independently ~~selected~~chosen from Re;

- Re is a group ~~selected~~chosen from alkyl, -OH, -ORc, $-NO_2$, halogen, -S(O)Rc, $-S(O)_2Rc$, -SRc, $-S(O)_2ORc$, -S(O)NRcRc, $-S(O)_2NRcRc$, -NRcRc, -

O(CRcRc)mNRcRc, -C(O)Rc, -CO_2Rc, -CO_2(CRcRc)mCONRcRc, -OC(O)Rc, -CN, -C(O)NRcRc, -NRcC(O)Rc, -OC(O)NRcRc, -NRcC(O)ORc, -NRcC(O)NRcRc, -CRc(N-ORc), -CFH_2, - CF_2H, -Ra, or -CF_3 ; wherein if two or more Rc groups are present these Rc groups may be the same or different; or ~~and any~~a pharmaceutically acceptable salt thereof;

or, when G is a carboxylic group in a compound of formula (I) or in a pharmaceutically acceptable salt of a compound of formula (I), a ~~as well as any~~ compound resulting from the esterification, with ~~any~~ an alcohol, of ~~the~~ said carboxylic group; ~~in the case where G is such a carboxylic group and any~~ or a pharmaceutically acceptable salt thereof.

2. (Currently Amended) A compound according to claim 1, wherein G is a COOH group ~~as well as any~~ or a compound resulting from the esterification, with an alcohol, of the COOH group.

3. (Currently Amended) A compound according to ~~any preceding claim~~ claim 1, wherein R3 and R4 are hydrogen atoms.

4. (Currently Amended) A compound according ~~any preceding claim~~ to claim 1, wherein R1 and R2 are each independently ~~selected~~chosen from hydrogen atoms, ~~and~~ alkyl, cycloalkyl, heterocyclylalkyl, aryl, arylalkyl, and heteroarylalkyl groups, wherein each of said alkyl, alkenyl, ~~and~~ alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups ~~or moieties are~~ is independently unsubstituted or substituted;

or R1 and R2 form, together with the nitrogen atom to which they are attached, ~~either~~ a 5- to 8- membered monocyclic heterocyclic ring system wherein said ring system comprises from 1 to 4 heteroatoms ~~selected~~chosen from nitrogen, oxygen and sulphur; and wherein said ring system is unsubstituted or substituted.

5. (Currently Amended) A compound according to ~~any preceding claim~~ claim 1, wherein R5 is ~~selected~~chosen from ~~the group consisting of~~ a 6- to 14- membered monocyclic or polycyclic aryl and a 5- to 14- membered monocyclic or polycyclic heteroaryl group~~s~~ comprising from 1 to 5 heteroatoms ~~selected~~chosen from nitrogen, oxygen and sulphur; wherein each of said aryl and heteroaryl groups ~~or moieties are~~ is independently unsubstituted or substituted.

6. (Currently Amended) A compound according to claim 5, wherein each of said aryl ~~or~~ and heteroaryl groups ~~are~~is independently unsubstituted or substituted by one or more halogen atoms.

7. (Currently Amended) A compound according to ~~any preceding claim~~ claim 1, wherein L1 is a group ~~selected~~chosen from -NH-, -O- and -NHCO-.

8. (Currently Amended) A compound according to ~~any preceding claim~~ claim 1, wherein R5–L1- is ~~selected~~chosen from ~~the group comprising~~ benzamide, isonicotinamide, 2,6-naphthyridin-1-ylamino, 2,7-naphthyridin-1-ylamino; 2,6-naphthyridin-1-yloxy and 2,7-naphthyridin-1-yloxy wherein said groups are unsubstituted or substituted.

9. (Currently Amended) A compound according to ~~any preceding claim~~ claim 1, wherein n is zero.

10. (Currently Amended) A compound according to ~~any preceding claim~~ claim 1 ~~which is one of~~ chosen from:

- (2*S*)-2-{[(tert-butylamino)sulfonyl]amino}-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionic acid
- Methyl (2*S*)-2-(*N*-benzylaminosulfonilamino)-3-[4-(2,6-dichlorobenzoylamino)phenyl]propionate
- (2*S*)-2-(*N*-benzylaminosulfonilamino)-3-[4-(2,6-dichlorobenzoylamino)phenyl]propionic acid
- Methyl (2*S*)-3-{4-[(2,6-dichlorobenzoyl)amino]phenyl}-2-{[(dimethylamino)sulfonyl]amino} propionate
- (2*S*)-3-{4-[(2,6-dichlorobenzoyl)amino]phenyl}-2-{[(dimethylamino)sulfonyl]amino} propionic acid
- Methyl (2*S*)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-{[(dimethylamino)sulfonyl]amino}propionate
- (2*S*)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-{[(dimethylamino)sulfonyl]amino}propionic acid
- Methyl (2*S*)-3-(4-{[1-(2,6-dichlorophenyl)methanoyl]amino}phenyl)-2-(piperidine-1-sulfonylamino)propionate
- (2*S*)-3-(4-{[1-(2,6-dichlorophenyl)methanoyl]amino}phenyl)-2-(piperidine-1-sulfonylamino)propionic acid

- Methyl (2*S*)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-{[(diisobutylamino)sulfonyl]amino}propionate
- (2*S*)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-{[(diisobutylamino)sulfonyl]amino}propionic acid
- Methyl (2*S*)-2-({[benzyl(ethyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionate
- (2*S*)-2-{[(benzylethylamino)sulfonyl]amino}-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionic acid
- Methyl (2*S*)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-{[(dibutylamino)sulfonyl]amino}propionate
- (2*S*)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-{[(dibutylamino)sulfonyl]amino}propionic acid
- Methyl (2*S*)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-({[[2-(3,4-dimethoxyphenyl)ethyl]isobutylamino]sulfonyl}amino)propionate
- (2*S*)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-({[[2-(3,4-dimethoxyphenyl)ethyl]isobutylamino]sulfonyl}amino)propionic acid
- Methyl (2*S*)-2-({[bis(thien-2-ylmethyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionate
- (2*S*)-2-({[bis(thien-2-ylmethyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionic acid
- Methyl (2*S*)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-({[methyl(2-pyridin-2-ylethyl)amino]sulfonyl}amino)propionate

- (2*S*)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-({[methyl(2-pyridin-2-ylethyl)amino]sulfonyl}amino)propionic acid
- Methyl (2*S*)-2-{[(cyclohexylmethylamino)sulfonyl]amino}-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionate
- (2*S*)-2-{[(cyclohexylmethylamino)sulfonyl]amino}-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionic acid
- Methyl (2*S*)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-({[(3-methylbutyl)(thien-2-ylmethyl)amino]sulfonyl}amino)propionate
- (2*S*)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-({[(3-methylbutyl)(thien-2-ylmethyl)amino]sulfonyl}amino)propionic acid
- Methyl (2*S*)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-[(piperidin-1-ylsulfonyl)amino]propionate
- (2*S*)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-[(piperidin-1-ylsulfonyl)amino]propionic acid
- Methyl (2*S*)-2-[(azepan-1-ylsulfonyl)amino]-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionate
- (2*S*)-2-[(azepan-1-ylsulfonyl)amino]-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionic acid
- Methyl (2*S*)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-[(morpholin-4-ylsulfonyl)amino]propionate
- (2*S*)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-[(morpholin-4-ylsulfonyl)amino]propionic acid

- Methyl (2*S*)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-[(thiomorpholin-4-ylsulfonyl)amino]propionate
- (2*S*)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-[(thiomorpholin-4-ylsulfonyl)amino]propionic acid
- Methyl (2*S*)-2-{[(dimethylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionate
- (2*S*)-2-{[(dimethylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionic acid
- Methyl (2*S*)-2-{[(diisobutylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionate
- (2*S*)-2-{[(diisobutylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionic acid
- Methyl (2*S*)-2-{[(diisobutylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionate
- (2*S*)-2-{[(diisobutylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionic acid
- Methyl (2*S*)-3-{4-[(2,6-dichlorobenzoyl)amino]phenyl}-2-{[(2,6-dimethylpiperidin-1-yl)sulfonyl]amino}propionate
- (2*S*)-3-{4-[(2,6-dichlorobenzoyl)amino]phenyl}-2-{[(2,6-dimethylpiperidin-1-yl)sulfonyl]amino}propionic acid
- Methyl (2*S*)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-{[(diisopropylamino)sulfonyl]amino}propionate

- (2*S*)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-{[(diisopropylamino)sulfonyl]amino}propionic acid
- Methyl (2*S*)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-{[(2,6-dimethylpiperidin-1-yl)sulfonyl]amino}propionate
- (2*S*)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-{[(2,6-dimethylpiperidin-1-yl)sulfonyl]amino}propionic acid
- Methyl (2*S*)-2-{[(dimethylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionate
- (2*S*)-2-{[(dimethylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionic acid
- Methyl (2*S*)-2-{[(diisopropylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionate
- (2*S*)-2-{[(diisopropylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionic acid
- Methyl (2*S*)-2-({[cyclohexyl(isopropyl)amino]sulfonyl}amino)-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionate
- (2*S*)-2-({[cyclohexyl(isopropyl)amino]sulfonyl}amino)-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionic acid
- Methyl (2S)-2-{[(diisopropylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionate
- (2S)-2-{[(diisopropylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionic acid

- Methyl (2S)-2-{[(diisopropylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionate
- (2S)-2-{[(diisopropylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionic acid
- Methyl (2*S*)-2-{[(2,6-dimethylpiperidin-1-yl)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionate
- (2*S*)-2-{[(2,6-dimethylpiperidin-1-yl)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionic acid
- Methyl (2*S*)-2-{[(2,6-dimethylpiperidin-1-yl)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionate
- (2*S*)-2-{[(2,6-dimethylpiperidin-1-yl)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionic acid
- Methyl (2*S*)-2-({[benzyl(isopropyl)amino]sulfonyl}amino)-3-{4-[(2,6-dichlorobenzoyl)amino]phenyl}propionate
- (2*S*)-2-({[benzyl(isopropyl)amino]sulfonyl}amino)-3-{4-[(2,6-dichlorobenzoyl)amino]phenyl}propionic acid
- Methyl (2*S*)-2-({[benzyl(isopropyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionate
- (2S)-2-({[benzyl(isopropyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionic acid
- Methyl (2*S*)-2-({[isopropyl(thien-2-ylmethyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionate

- (2*S*)-2-({[isopropyl(thien-2-ylmethyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionic acid
- Methyl (2*S*)-2-({[isopropyl(thien-2-ylmethyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichlorobenzoyl)amino]phenyl}propionate
- (2*S*)-2-({[isopropyl(thien-2-ylmethyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichlorobenzoyl)amino]phenyl}propionic acid
- Methyl (2*S*)-3-{4-[(2,6-dichloroisonicotinoyl)amino]phenyl}-2-[({isobutyl[(1*S*)-1-phenylethyl]amino}sulfonyl)amino]propionate
- (2*S*)-3-{4-[(2,6-dichloroisonicotinoyl)amino]phenyl}-2-[({isobutyl[(1*S*)-1-phenylethyl]amino}sulfonyl)amino]propionic acid
- Methyl (2*S*)-2-({[cyclopentyl(isopropyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionate
- (2*S*)-2-({[cyclopentyl(isopropyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionic acid
- Methyl (2*S*)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-({[isobutyl(isopropyl)amino]sulfonyl}amino)propionate
- (2*S*)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-({[isobutyl(isopropyl)amino]sulfonyl}amino)propionic acid
- Methyl (2*S*)-2-({[cyclohexyl(isopropyl)amino]sulfonyl}amino)-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionate
- (2*S*)-2-({[cyclohexyl(isopropyl)amino]sulfonyl}amino)-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionic acid

- Methyl (2*S*)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-[({isobutyl[(1R)-1-phenylethyl]amino}sulfonyl)amino]propionate
- (2*S*)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-[({isobutyl[(1R)-1-phenylethyl]amino}sulfonyl)amino]propionic acid
- Methyl (2*S*)-2-({[methyl(phenyl)amino]sulfonyl}amino)-3-{4-[(2,6-dichlorobenzoyl)amino]phenyl}propionate
- (2*S*)-2-({[methyl(phenyl)amino]sulfonyl}amino)-3-{4-[(2,6-dichlorobenzoyl)amino]phenyl}propionic acid
- Methyl (2S)-({[2-(phenylsulfonyl)phenyl]amino}sulfonyl)amino]-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionate; and
- (2S)-({[2-(phenylsulfonyl)phenyl]amino}sulfonyl)amino]-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionic acid;
- or a pharmaceutically acceptable salt thereof.

11. (Currently Amended) A process for producing a compound of ~~formula I as defined in any one of claims 1 to 10~~ claim 1, ~~which process comprises~~ comprising reacting an amine of formula (III):



~~wherein Rd, R3, R4, R5, R6, L1 and n are as defined in any one of claims 1 to 10~~

with a corresponding sulfamoyl chloride of formula (IV):



(IV)

~~wherein R1 and R2 are as defined in any one of claims 1 to 10~~ to produce a compound of formula (I); and

optionally producing a pharmaceutically acceptable salt of a compound of formula (I).

12. (Currently Amended) A process for producing a compound of ~~formula I as defined in any one of claims 1 to 10~~ claim 1, ~~which process comprises~~ comprising reacting an amine of formula (IIa):



(IIa)

~~wherein Rd, R3, R4, R5, R6, L1 and n are as defined in any one of claims 1 to 10~~

with an amine of formula (V)

(V)

~~wherein R1 and R2 are as defined in any one of claims 1 to 10~~ to produce a compound of formula (I); and

optionally producing a pharmaceutically acceptable salt of a compound of formula (I).

13. (Currently Amended) A process for producing a compound of ~~formula I as defined in any one of claims 1 to 10~~ claim 1, ~~which process comprises~~ comprising reacting an amine of formula (III):



(III)

~~wherein R3, R4, R5, R6, Rd, L1 and n are as defined in any one of claims 1 to 10~~ with a sulfamide of formula (VII):



(VII)

~~wherein R1 and R2 are as defined in any one of claims 1 to 10~~ to produce a compound of formula (I); and

optionally producing a pharmaceutically acceptable salt of a compound of formula (I).

14. (Currently Amended) A process for producing a compound of ~~formula I as defined in any one of claims 1 to 10~~ claim 1, ~~which process comprises~~comprising ~~the steps of~~:

~~(a)~~reacting an amine of formula (III):



(III)

~~wherein R3, R4, R5, R6, Rd, L1 and n are as defined in any one of claims 1 to 10~~ with tert-butanol and chlorosulfonyl isocyanate to yield the sulfamide of formula (VIII); ~~and~~



(VIII)

~~(b)~~reacting the sulfamide of formula (VIII) with an alcohol of formula (IX)~~.~~



(IX)

to produce a compound of formula (I); and

optionally producing a pharmaceutically acceptable salt of a compound of formula (I).

15. (Currently Amended) A process for producing a compound of ~~formula I as defined in any one of claims 1 to 10~~ claim 1, ~~which process comprises~~ comprising reacting an amine of formula (X):



(X)

~~wherein Rd, R3, R4, R5, R6, L1 and n are as defined in any one of claims 1 to 10~~ with an amine of formula (V)

(V)

~~wherein R1 and R2 are as defined in any one of claims 1 to 10~~ to produce a compound of formula (I); and

optionally producing a pharmaceutically acceptable salt of a compound of formula (I).

16. (Cancelled) ~~Use of a compound of formula I as defined in any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a pathological condition susceptible of being improved by antagonism of α4β1 and/or α4β7 integrins.~~

17. (Cancelled) ~~Use according to claim 16, wherein the medicament is for the treatment of a pathological condition susceptible of being improved by the inhibition or prevention of cell adhesion processes mediated by α4β1 and/or α4β7 integrins.~~

18. (Cancelled) ~~Use according to any one of claims 16 or 17, wherein the medicament is for the prevention or treatment of an immune or inflammatory disease or disorder susceptible of being improved by antagonism of α4β1 and/or α4β7 integrins.~~

19. (Cancelled) ~~Use according to any one of claims 16 to 18, wherein the pathological condition or disease is multiple sclerosis, asthma, allergic rhinitis, allergic conjunctivitis, an inflammatory lung disease, rheumatoid arthritis, polydermatomyositis, septic arthritis, type I diabetes, rejection following organ transplantation, restenosis, rejection following autologous bone marrow~~

~~transplantation, inflammatory sequelae of viral infections, atopic dermatitis, myocarditis, inflammatory bowel disease including ulcerative colitis and Chron's disease, certain types of toxic and immune based nephritis, contact dermal hypersensitivity, psoriasis, tumor metastasis, atherosclerosis or cerebral ischemia.~~

20. (Currently Amended) A pharmaceutical composition comprising an effective amount of a compound as defined in ~~any one of claims 1 to 10~~ claim 1, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.

21. (Currently Amended) A compound or a pharmaceutically acceptable salt thereof as defined in ~~any one of claims 1 to 10~~ claim 1, for use in a method of treatment of a subject afflicted with a pathological condition susceptible to amelioration by antagonism of $\alpha 4\beta 1$ and/or $\alpha 4\beta 7$ integrins.

22. (Currently Amended) A method for treating a subject afflicted with a pathological condition susceptible to amelioration by antagonism of $\alpha 4\beta 1$ and/or $\alpha 4\beta 7$ integrins, ~~which comprises~~comprising administering to said subject an effective amount of a compound ~~of formula I~~ as defined in ~~any one of claims 1 to 10~~ claim 1.

23. (Original) A method according to claim 22, wherein the pathological condition is susceptible to amelioration by the inhibition or prevention of cell adhesion processes mediated by $\alpha 4\beta 1$ and/or $\alpha 4\beta 7$ integrins.

24. (Currently Amended) A method according to ~~any one of claims 22 or 23~~ claim 22, wherein the pathological condition is an immune or inflammatory disease or disorder susceptible to amelioration by antagonism of $\alpha 4\beta 1$ and/or $\alpha 4\beta 7$ integrins.

25. (Currently Amended) A method according to ~~any one of claims 22 to 24~~ claim 22, wherein the pathological condition or disease is chosen from multiple sclerosis, asthma, allergic rhinitis, allergic conjunctivitis, an inflammatory lung disease, rheumatoid arthritis, polydermatomyositis, septic arthritis, type I diabetes, rejection following organ transplantation, restenosis, rejection following autologous bone marrow transplantation, inflammatory sequelae of viral infections, atopic dermatitis, myocarditis, inflammatory bowel disease including ulcerative colitis and Chron's disease, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, psoriasis, tumor metastasis, atherosclerosis ~~or~~ and cerebral ischemia.